AstraZeneca PLC CEO Defends Strategy Amid Shareholder Demands and Questions for Change

David Brennan said his leadership as chief executive officer of London-based drugmaker AstraZeneca Plc (AZN) remains steady amid reports that some shareholders are seeking a change. “I’m plugged in, my role hasn’t changed a bit,” Brennan said in an interview in Boston, where he was attending the annual meeting of the Pharmaceutical Research and Manufacturers of America. “I read and hear and see lots of things, but we’re here trying to change policy, make good decisions and execute our strategy.”

Back to news